A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival

Halle, Mari K.; Munk, Ane Cecilie; Engesæter, Birgit; Akbari, Saleha; Frafjord, Astri; Høivik, Erling A.; Forsse, David; Fasmer, Kristine Eldevik; Woie, Kathrine; Haldorsen, Ingfrid S.; Bertelsen, Bjørn; Janssen, E. A. M.; Gudslaugsson, Einar; Krakstad, Camilla; Øvestad, Irene Tveiterås

doi:10.3390/cancers13225737

Cited by 13 publications

(7 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we identified that TDO2 is highly expressed in 20 types of cancer, including BLCA, BRCA, CESC, COAD, ESCA, GBM, HNSC, KIRC, LUAD, LUSC, OV, PAAD, PRAD, READ, SKCM, STAD, TGCT, THCA, UCEC, and UCS, which are in line with previous findings [8][9][10][24][25][26][27][28]. However, Wu et al found that TDO2 was overexpressed in HCC, and their overexpression was correlated with tumor progression and poor prognosis [29,30], which contradicts our current results.…”

Section: Discussionsupporting

confidence: 93%

Pancancer Analysis of Revealed TDO2 as a Biomarker of Prognosis and Immunotherapy

et al. 2022

View full text Add to dashboard Cite

Background. Tryptophan 2,3-dioxygenase (TDO) encoded by TDO2, a rate-limiting enzyme in the kynurenine pathway, catabolizes tryptophan to kynurenine, evades immune surveillance, and promotes tumor growth. Although accumulating evidence suggests a crucial role of TDO2 during tumor formation and development, systematic evaluation of TDO2 across human cancers has rarely been reported. Methods. To shed more light on the role of TDO2 in human cancer, we explored the expression profiles of TDO2 and identified its prognostic value in pancancer analysis through TCGA, CCLE, and GTEx databases. We further utilized TCGA data to evaluate the association between TDO2 and tumor immunological features, such as mismatch repair (MMR), tumor immune infiltration, immune checkpoint-related genes, tumor mutational burden (TMB), microsatellite instability (MSI), and DNA methyltransferase (DNMT). Results. TDO2 exhibited different expression levels in various cancer cell lines. Frequently, TDO2 was detected to be highly expressed in the majority of cancers. In addition, high TDO2 expression was correlated with an unfavorable prognosis for patients in KIRP, LGG, TGCT, and UVM. Moreover, high TDO2 expression level positively correlated with higher immune infiltration, especially dendritic cells. Additionally, there is a close relationship between TDO2 and immune checkpoint-related gene markers, such as LAIR1, CD276, NRP1, CD80, and CD86. Finally, correlation analysis has demonstrated a high-correlation between TDO2 and TMB, MSI, MMR, and DNMT of multiple cancer types. Conclusion. Therefore, our results suggest that TDO2 can function as a potential prognostic biomarker due to its role in tumor immunity regulation.

show abstract

Section: Discussionsupporting

confidence: 93%

Pancancer Analysis of Revealed TDO2 as a Biomarker of Prognosis and Immunotherapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The patients were randomly assigned to a training group and a testing group. The gene expression pro les were merged and normalized using the 'sva' package [9] in R (v4.1.0).…”

Section: Datasets and Pre-processingmentioning

confidence: 99%

Necroptosis-associated long noncoding RNA predicts prognosis for cervical cancer in a microenvironment signature associated with anti-tumor immune responses

Yang,

Ma,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Cancer has high incidence rate, poor prognosis and high intratumoral heterogeneity. Necrosis is an important cellular signaling pathway in tumor cells, which can overcome the resistance of tumor cells to apoptosis. To investigate the relationship between CC and necrosis, we established a prognostic model based on necrosis related genes to predict the overall survival (OS) of CC patients. Methods: We obtained gene expression data and clinical information of cervical cancer patients from the Cancer Genome Map (TCGA). By detecting differential gene expression between tumors and normal tissues, 43 differentially expressed necrosis related lncRNAs (NRLs) were identified. Subsequently, the Least Absolute Shrinkage and Selection Operator (LASSO) regression and univariate and multivariate Cox regression analysis were used to screen for NRLs associated with patient prognosis. We have established prognostic markers including AC022137.3, AC024270.3, AC010542.5, AC010536.2, U91328.1, and AL021978.1. According to the prognosis model, patients are divided into high-risk or low-risk subgroups with different survival rates. The receiver operating characteristic (ROC) curve analysis is used to determine the predictive accuracy of the model. We conducted stratified analysis on different clinical variables to demonstrate the correlation between the expression level of NRLs identified and clinical variables. We also explored the relationship between the prognostic NRLs and immune-cell infiltration and immune checkpoints. Results: Based on the differently expressed lncRNAs, we constructed lncRNA signatures. The area under the curve (AUC) of the ROC curve is used to predict 5-year survival rate with a characteristic of 0.757. Subsequent analysis indicates that our features can effectively distinguish adverse survival outcomes. High expression of immune checkpoint related lncRNAs is associated with low risk groups. Conclusion: We have constructed a new necrosis related lncRNA signal for predicting the prognosis of CC patients and may play a key role in the progression and immune microenvironment of CC.

show abstract

“…Finally, the expression of phosphoglycerate dehydrogenase rises continuously as CIN progresses to cancer. Phosphoglycerate dehydrogenase is believed to be involved in carcinogenesis and might be used to predict CIN development [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Low-Grade Cervical Intraepithelial Neoplasia (CIN1) Evolution: Analysis of Opportunistic Preventive Vaccination Role

et al. 2023

View full text Add to dashboard Cite

Background: Low-grade cervical lesions have a high percentage of clearance in young women, even if 71–82% of low-grade intraepithelial lesion/atypical squamous cells of undetermined significance (LSIL/ASCUS) reported a High-Risk Human Papillomavirus (HR-HPV) infection, which correlates with an increased risk of Cervical Intraepithelial Neoplasia (CIN)2+. The immunogenic effect of the anti-HPV vaccine appears to be significant. The aim of the study is to evaluate the effect, two years after the diagnosis, of the anti-HPV preventive vaccination on patients with low-grade cervical lesions. Methods: We collected clinical, colposcopic, histological, and virological data from patients aged 21–45 years who attended the colposcopy service of the department of Obsetrics and Gynecology of IRCCS Foundation Policlinico San Matteo, Pavia, Italy. In the 2005–2019 period and had a low-grade pap-smear. Results: We enrolled 422 women consecutively, divided into two groups (vaccinated and not vaccinated) for the retrospective analysis. The rate of persistence and progression of CIN were higher in the not-vaccinated group (p = 0.019). The relative risk (RR) to develop CIN2+ during follow-up vs. the the CIN1 persistence was 1.005 (95% Confidence Interval—CI 0.961–1.051) vs. 0.994 (95% CI 0.994–1.018) for age, 3.472 (95% CI 1.066–11.320) vs. 1.266 (95% CI 0.774–2.068) for non-vaccinated, 0.299 (95% CI 0.088–1.018) vs. 0.518 (95% CI 0.242–1.109) for HIV status negative, respectively. Analyzing the time to negativity, the odds ratio (OR) was 1.012 (95% CI 1–1.024) for age and 1.591 (95% CI 1.223–2.069) for vaccination; on the other hand, considering the relationship between the time to negative and the HPV genotypes contained in the 9-valent HPV vaccines, the OR was 1.299 (95% CI 1.026–1.646) for at least one of these at recruitment and 0.631 (95% CI 0.471–0.846) at follow-up. Furthermore, the presence of at least one of the HPV genotypes targeted by the HPV nonavalent vaccine is a key indicator of the risk of progression to CIN2+: OR was 3.443 (95% CI 1.065–11.189) for the presence of at least one HPV genotype at enrollment and 5.011 (95% CI 1.899–13.224) for the presence of at least one HPV genotype at follow-up, respectively. Conclusions: We reported in a retrospective study the benefit of anti-HPV vaccination in promoting negativity and increasing low-grade cervical lesions regression.

show abstract

A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival

Cited by 13 publications

References 74 publications

Pancancer Analysis of Revealed TDO2 as a Biomarker of Prognosis and Immunotherapy

Pancancer Analysis of Revealed TDO2 as a Biomarker of Prognosis and Immunotherapy

Necroptosis-associated long noncoding RNA predicts prognosis for cervical cancer in a microenvironment signature associated with anti-tumor immune responses

Low-Grade Cervical Intraepithelial Neoplasia (CIN1) Evolution: Analysis of Opportunistic Preventive Vaccination Role

Contact Info

Product

Resources

About